Injectable / Weight Loss & GLP-1
GLP-2 Tirze
Dual GIP/GLP-1 Agonist · 16.5mg
$149 USD per unit · In stock · 16.5mg / 2mL vial
Dual-action incretin mimetic targeting both GIP and GLP-1 receptors. The next generation of metabolic peptide therapy.
Product information
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. This dual mechanism produces superior weight loss and glycemic outcomes compared to single-receptor agonists.
Each multi-dose vial is filled to 16.5mg of pharmaceutical-grade tirzepatide, as stated on the box. Clinical trials demonstrate up to 22.5% body weight reduction, the most significant results achieved by any metabolic peptide to date.
Benefits
- Dual GIP/GLP-1 receptor activation
- Superior weight loss outcomes
- Enhanced glycemic control
- Improved metabolic biomarkers
Specifications
- Fill / pack
- 16.5mg / 2mL vial
- Format
- Injectable
- Serving
- 2.5-15mg weekly
- Servings per container
- 4-8 weeks supply
- Listed purity
- 99.54%
- Molecular weight / composition
- 4813.45 Da
- Storage
- Refrigerate 2-8°C
Frequently asked questions
How should I store this product?
Refrigerate at 2-8°C. Keep away from direct light. Once reconstituted, use within 30 days.
How long until I see results?
Most users report initial effects within 2-4 weeks, with optimal results typically observed after 8-12 weeks of consistent use. Individual responses vary.
Is a Certificate of Analysis included?
Yes. Every order includes a batch-specific COA with HPLC purity analysis, amino acid sequence verification, and endotoxin testing results.
What injection method is recommended?
Subcutaneous injection is standard. Rotate injection sites. Detailed protocol guidance is available on every product page.
For laboratory and research use only. Not for human consumption.
Browse all peptide bioregulators or the Weight Loss & GLP-1 collection. All formulations.